Peptide Protocol
Peptide Protocol
 App Store

Orforglipron: the complete guide

Orforglipron is an oral non-peptide small-molecule GLP-1 receptor agonist. Unlike semaglutide-in-Rybelsus, orforglipron does not require fasting or special absorption conditions, positioning it as a potential first-line oral GLP-1 therapy.

Written by Peptide Protocol Editorial Medically reviewed per our review process Last reviewed
ClassNon-peptide oral GLP-1 receptor agonist
Half-lifeApproximately 29–49 hours (once-daily oral dosing)
Typical doseTrial titration: 3 → 12 → 24 → 36 mg oral once daily
CategoryMetabolic / GLP-1
Research useOral GLP-1 alternative research, type 2 diabetes, obesity
FDA statusInvestigational. Not FDA approved. Phase III trials ongoing in obesity and type 2 diabetes.

How Orforglipron works

Orforglipron is a non-peptide agonist at the GLP-1 receptor with a different binding mode than peptide agonists. It produces GLP-1-mediated appetite suppression, insulin secretion, and slowed gastric emptying without the strict administration rules of oral semaglutide.

Typical Orforglipron dosage

Commonly reported research ranges: Trial titration: 3 → 12 → 24 → 36 mg oral once daily.

Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.

Administration

Orforglipron is taken orally — no reconstitution is required. Follow the manufacturer's guidance for liquid or capsule dosing.

Half-life and administration frequency

Approximately 29–49 hours (once-daily oral dosing).

This half-life informs how often Orforglipron is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.

Reported side effects

This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.

Common Orforglipron stacks

Storage and handling

Oral tablet, room temperature (trial formulation).

FDA and regulatory status

Investigational. Not FDA approved. Phase III trials ongoing in obesity and type 2 diabetes.

Orforglipron clinical trials and evidence

For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.

Track your Orforglipron protocol on iPhone

Peptide Protocol logs every dose, calculates reconstitution for you, and keeps your full protocol on one calm screen.

See the app →

Frequently asked questions

What is Orforglipron?

Orforglipron is an oral non-peptide small-molecule GLP-1 receptor agonist. Unlike semaglutide-in-Rybelsus, orforglipron does not require fasting or special absorption conditions, positioning it as a potential first-line oral GLP-1 therapy.

How does Orforglipron work?

Orforglipron is a non-peptide agonist at the GLP-1 receptor with a different binding mode than peptide agonists. It produces GLP-1-mediated appetite suppression, insulin secretion, and slowed gastric emptying without the strict administration rules of oral semaglutide.

What is a typical Orforglipron dose?

Commonly reported ranges are Trial titration: 3 → 12 → 24 → 36 mg oral once daily. This is research information, not a recommendation — dosing should be individualized under clinical guidance.

What is the half-life of Orforglipron?

Approximately 29–49 hours (once-daily oral dosing). This influences how often it is taken.

Does Orforglipron require reconstitution?

Orforglipron is not handled as a standard lyophilized injectable reconstitution page in this database. Follow the manufacturer, study protocol, or clinician instructions for the specific formulation.

What are the side effects of Orforglipron?

Nausea and GI effects during titration; Vomiting; Diarrhea or constipation; Limited long-term data.

Is Orforglipron FDA approved?

Investigational. Not FDA approved. Phase III trials ongoing in obesity and type 2 diabetes.

Are there clinical trials for Orforglipron?

Registered or published clinical-trial sources for Orforglipron are listed in the references section below. Evidence depth varies widely by compound, so check the cited trial registries and primary literature before relying on any claim.

References

  1. Orforglipron literature (PubMed) — National Library of Medicine. Primary research on orforglipron development and trials
  2. Orforglipron clinical trial records — ClinicalTrials.gov. Phase II/III trials in obesity and T2D
  3. Wharton et al. — Orforglipron Phase II obesity results — PubMed. Key Phase II obesity trial publication

Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.

Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.